@IOBiotech today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Read the full press release here: bit.ly/3YPUOCS

We are delighted to share that members of our @IOBiotech management team will be heading to San Francisco in just a few short weeks to for partnership and investor meetings on January 12-15. If you’ll be in San Francisco, we would welcome the opportunity to connect to discuss our lead investigational candidate, Cylembio, and the other candidates in our pipeline of novel off-the-shelf, immune- modulatory therapies with pan-cancer potential. Please reach out if you would like to meet with any of our team members by emailing us at [email protected]. #JPM2026 #CancerImmunotherapy #InvestorConferences

@IOBiotech is pleased to announce the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both tumor cells and immune-suppressive cells expressing IDO1 and/or PD-L1, in combination with PD-1 blockade in the treatment of first line metastatic melanoma. Read the full press release with a link to the article here: bit.ly/3MDiJCI #IOBiotech #CancerImmunotherapy #cancer

@IOBiotech is very pleased to announce that our President and CEO, Mai-Britt Zocca, PhD, will be a Speaker in the Special session with Industry, “How to translate IO research from academia to biotech”, at the ESMO Immuno-Oncology Congress 2025 taking place in London December 10 – 12, 2025. The Congress is an international event that brings together immune-oncology experts to learn, share research and expertise, and connect with other stakeholders that are making a difference in the immune-oncology field. Lecture title: IO-Biotech: Ten years journey to change the landscape of cancer vaccines Date and time: Thursday, December 11, 2025, from – GMT Learn more about the full program here: bit.ly/445Yof1 #IOBiotech #CancerImmunotherapy

@IOBiotech is pleased to announce that members of its executive management team will be attending the following upcoming December investor conferences: Event: 8th Annual Evercore Healthcare Conference Location: Coral Gables, Florida Fireside chat: Tuesday, December 2, 2025, at 7:55 am ET Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO Event: Piper Sandler 36th Annual Healthcare Conference Location: New York, New York Fireside chat: Wednesday, December 3, 2025, at 3:00 pm ET Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO See the full press release for more details and webcast links: bit.ly/4rlbcYL #IOBiotech #cancer #InvestorConferences

@IOBiotech today reported financial results for the third quarter of 2025. Read more here: bit.ly/4oJnclo #IOBiotech #cancervaccines #financialresults

@IOBiotech is pleased to announce that members of its executive management team will be attending the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference Format: Company presentation Date: Tuesday, November 18, 2025, 3:00 PM GMT Presenter: Mai-Britt Zocca, PhD, President & CEO Event: Piper Sandler 36th Annual Healthcare Conference Format: Fireside chat Date: Wednesday, December 3, 2025, 3:00 PM ET Participants: Mai-Britt Zocca, PhD, President & CEO and Amy Sullivan, CFO See the full press release for more details: bit.ly/4oBy18V #IOBiotech #cancer #InvestorConferences

We are pleased to have Inés Lecoq Molinos, PhD, Senior Scientist, at the SITC Annual Meeting today to present preclinical findings on the potential of our novel investigational immune-modulatory vaccine, IO170 targeting TGF-β, to potentially enhance the treatment efficacy for a wide range of cancers. To learn more, visit the poster presentation today, November 8th from 12:15 – 1:45 PM ET in Exhibit Halls AB.

@IOBiotech today announced new pre-clinical data for its next vaccine candidate IO112 targeting arginase 1 and additional candidate IO170 targeting TGF-β, will be presented at the SITC Annual Meeting taking place in Maryland on November 5-9, 2025. Read the full press release here: bit.ly/4qLVKov